Gerresheimer Ends Takeover Talks to Focus on Strategic Growth

Gerresheimer AG has decided to cease discussions with private equity investors about a potential takeover. The decision reflects the company's judgment that continuing talks does not align with the interests of its stakeholders. Instead, the company will concentrate on executing its growth strategy within the pharma, biotech, and cosmetics sectors.

A strategic review of its Moulded Glass business is set to accelerate. This follows the acquisition of Bormioli Pharma, enhancing Gerresheimer's product offerings. The integration aims to create a stronger, globally active unit providing diverse primary glass packaging solutions.

Gerresheimer anticipates presenting a strategy update on October 15, 2025, emphasizing high-growth areas like biologics. The company expects mid-term organic revenue growth of 6-9% alongside an adjusted EBITDA margin of 23-25%.